NASDAQ:EYPT Eyepoint Pharmaceuticals Q2 2024 Earnings Report $13.58 +0.08 (+0.59%) Closing price 04:00 PM EasternExtended Trading$13.26 -0.32 (-2.36%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eyepoint Pharmaceuticals EPS ResultsActual EPS-$0.58Consensus EPS -$0.55Beat/MissMissed by -$0.03One Year Ago EPSN/AEyepoint Pharmaceuticals Revenue ResultsActual Revenue$9.48 millionExpected Revenue$11.61 millionBeat/MissMissed by -$2.13 millionYoY Revenue GrowthN/AEyepoint Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/7/2024TimeBefore Market OpensConference Call DateWednesday, August 7, 2024Conference Call Time7:15AM ETUpcoming EarningsEyepoint Pharmaceuticals' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Eyepoint Pharmaceuticals Earnings HeadlinesEyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by BrokeragesMay 27 at 2:16 AM | americanbankingnews.comEyePoint Pharmaceuticals (EYPT) Gets a Buy from GuggenheimMay 24, 2026 | theglobeandmail.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.May 29 at 1:00 AM | American Alternative (Ad)EyePoint Announces Participation at Upcoming Investor ConferencesMay 19, 2026 | globenewswire.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)May 14, 2026 | theglobeandmail.comSee More Eyepoint Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eyepoint Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyepoint Pharmaceuticals and other key companies, straight to your email. Email Address About Eyepoint PharmaceuticalsEyepoint Pharmaceuticals (NASDAQ:EYPT) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States. Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery. Both products leverage sustained-release technology to deliver corticosteroids directly to ocular tissues, aiming to reduce treatment frequency and improve patient compliance compared with traditional eye drop approaches. The company secured FDA approvals for both YUTIQ and DEXYCU in late 2018 and commenced U.S. commercial launches in 2019. Eyepoint is headquartered in New York, with additional facilities supporting manufacturing and clinical development efforts. Since its inception, the company has entered into multiple licensing agreements to expand its product portfolio and explore new ophthalmic indications, while also advancing preclinical programs investigating sustained-release therapies for other retinal and anterior segment disorders. Eyepoint is led by James A. Mazzo, who serves as Chairman, President, and Chief Executive Officer. Under his leadership, the company has built a specialized commercial organization and forged strategic collaborations to broaden its market reach. Eyepoint continues to invest in research and development to enhance its sustained-release platform and pursue additional regulatory milestones that may address unmet needs in ophthalmology.View Eyepoint Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Shares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysDollar Tree Keeps Winning After Family Dollar DivorceSalesforce Stock Finds Support as AI Momentum BuildsMarvell’s Pullback May Be the Setup Bulls Were Waiting ForSnowflake and the Snowballing Impact of its AI FlywheelPalomar’s High-Risk Insurance Strategy Is Paying Off BigThis Quantum Computing Stock May Be Closer to a Breakout Than You Think Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
